Disclosures for "Evaluation of the Indirect and Nonmedical Impacts of Generalized Myasthenia Gravis on Patients and Caregivers"
-
Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Strongbridge. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Gwathmey has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Gwathmey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals.
-
Dr. Yee has received personal compensation for serving as an employee of Alexion. Dr. Yee has stock in Alexion. Dr. Yee has stock in Takeda.
-
Ms. Foss has received personal compensation for serving as an employee of Myasthenia Gravis Association. Ms. Foss has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Ms. Foss has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Ms. Foss has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant.
-
Mrs. Ramirez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Mrs. Ramirez has a non-compensated relationship as a Founder & Board Treasurer with Own MG that is relevant to AAN interests or activities.
-
Ms. Sullivan has received personal compensation for serving as an employee of EveryLife Foundation for Rare Diseases. An immediate family member of Ms. Sullivan has received personal compensation for serving as an employee of Takeda. Ms. Sullivan has received personal compensation in the range of $5,000-$9,999 for serving as a Policy Advisor with COPD Foundation.
-
Dr. dosReis has nothing to disclose.
-
Dr. Thiele has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HEALTH MANAGEMENT ASSOCIATION.
-
Mr. Schwartz has received personal compensation for serving as an employee of Avalere. Mr. Schwartz has received personal compensation for serving as an employee of Inovalon. The institution of Mr. Schwartz has received research support from Life Sciences Organizations.
-
Nicole Betor has received personal compensation for serving as an employee of Avalere.
-
Ms. Hunt has received personal compensation for serving as an employee of Avalere .
-
Ms. Rebeira has stock in Alexion, Astrazeneca Rare Disease.
-
Dr. Narayanaswami has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. Dr. Narayanaswami has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Narayanaswami has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Narayanaswami has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CVS. Dr. Narayanaswami has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Narayanaswami has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Narayanaswami has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx USA. Dr. Narayanaswami has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Narayanaswami has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Narayanaswami has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NMD pharma. Dr. Narayanaswami has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for serono. Dr. Narayanaswami has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Muscle and Nerve, Wiley. Dr. Narayanaswami has stock in Dr. Reddys laboratories. Dr. Narayanaswami has stock in Pfizer. Dr. Narayanaswami has stock in Doximity. The institution of Dr. Narayanaswami has received research support from Alexion. The institution of Dr. Narayanaswami has received research support from Dianthus. Dr. Narayanaswami has received publishing royalties from a publication relating to health care. Dr. Narayanaswami has a non-compensated relationship as a Member, Medical and Scientific Council with Myasthenia Gravis Foundation of America that is relevant to AAN interests or activities. Dr. Narayanaswami has a non-compensated relationship as a Member, Board of Directors with AANEM that is relevant to AAN interests or activities.